Monitoring tumor burden by multicolor in vivo flow cytometry
Date Issued
September 28, 2013
Abstract
In vivo measurement of tumor burden, both in cancer research models and in patients, is an important parameter
for the accurate assessment of disease progression and the response to therapeutic intervention [1]. Several in
vivo imaging modalities have been utilized in the assessment of tumor burden, including functional magnetic
resonance imaging, computer tomography and positron emission tomography [2, 3], fluorescence imaging [4, 5],
intravital microscopy [6] and bioluminescence imaging [7]. More recently, the detection/quantification of
circulating cancer cells has been explored as a method to evaluate tumor burden in the context of assessing
disease stage, prognosis as well as monitoring disease progression following therapeutic intervention in cancer
patients [8, 9]. Clinically, various ex vivo assays have been developed to detect cancer cells shed in circulation
by primary tumors, including breast cancer, prostate cancer and small-cell lung cancer [10, 11].
In vivo flow cytometry has been developed as a method for real-time detection of circulating cancer cells
injected into the circulation of experimental animals. The method does not require extraction of blood samples
and is therefore well suited for long-term monitoring of circulating tumor cells. In this report, we report on the
development of a multichannel in vivo flow cytometer to detect and quantify circulating cancer cells as a means
of assessing the tumor burden in animal models.
for the accurate assessment of disease progression and the response to therapeutic intervention [1]. Several in
vivo imaging modalities have been utilized in the assessment of tumor burden, including functional magnetic
resonance imaging, computer tomography and positron emission tomography [2, 3], fluorescence imaging [4, 5],
intravital microscopy [6] and bioluminescence imaging [7]. More recently, the detection/quantification of
circulating cancer cells has been explored as a method to evaluate tumor burden in the context of assessing
disease stage, prognosis as well as monitoring disease progression following therapeutic intervention in cancer
patients [8, 9]. Clinically, various ex vivo assays have been developed to detect cancer cells shed in circulation
by primary tumors, including breast cancer, prostate cancer and small-cell lung cancer [10, 11].
In vivo flow cytometry has been developed as a method for real-time detection of circulating cancer cells
injected into the circulation of experimental animals. The method does not require extraction of blood samples
and is therefore well suited for long-term monitoring of circulating tumor cells. In this report, we report on the
development of a multichannel in vivo flow cytometer to detect and quantify circulating cancer cells as a means
of assessing the tumor burden in animal models.
File(s)![Thumbnail Image]()
Name
Monitoring tumor burden by multicolor in vivo flow.pdf
Size
183.74 KB
Format
Adobe PDF
Checksum (MD5)
aab22257cf3432c60ac012413a55518e